ASCO Preview - Two interesting Studies

The ASCO meeting abstracts are posted online. Here are two studies highlighted on Cancer.net.

Long-Term Treatment with Olaparib May Help Treat Recurrent Ovarian Cancer

This PARP inhibitor is effective in extending the progression-free survival of recurrent patients with an inherited version of a DNA deficiency as well as a non-inherited version. Interesting study. I can't wait to hear more about olaparib. Here is a Med-Page link that explains the study further.

Screening Does Not Reduce Deaths from Ovarian Cancer for the General Population

This large ( 80,000 particpant) study highlights the need for further research to find a a screening test for the general public for ovarian cancer. CA-125 and Ultrasound together to screen for the disease did not reduce mortality numbers.

Dee

Every Day is a Blessing!

Screening Can Detect Early Ovarian Cancer - NY Times

As reported in the NY Times "postmenopausal women who are screened for ovarian cancer either by transvaginal ultrasound scan or by a blood test followed by a scan are more likely to have their cancers detected at early stages, with almost half the cancers picked up before they had spread beyond the pelvis."
For the complete NY Times article click here.

The results of the study were printed online at The Lancet Oncology.


Livestrong

Dee
Every Day is a blessing!